Psicologia e Saúde em Debate
January 10, 2024
Leonardo Hercílio Florêncio Silva, Júnia Aparecida Laia Da Mata, Sabrina Stefanello et al.
Psilocybin is a natural substance with hallucinogenic properties that has recently been used in the field of health. It is an alkaloid that, when associated with psychotherapy, has shown benefits in the treatment of depression and anxiety. This study aims to analyze the current state of knowledge about the psychological effects of psilocybin in patients with terminal cancer. The method used was...
Science Translational Medicine
January 10, 2024
Katie Kamenish, Roberto Arban, Aslihan Selimbeyoglu et al.
26 citations
How rapid-acting antidepressants (RAADs), such as ketamine, induce immediate and sustained improvements in mood in patients with major depressive disorder (MDD) is poorly understood. A core feature of MDD is the prevalence of cognitive processing biases associated with negative affective states, and the alleviation of negative affective biases may be an index of response to drug treatment....
Proceedings of the National Academy of Sciences
January 9, 2024
Virginia Ramírez-Cruz, Giuliana Furci, Alexander J. Bradshaw et al.
30 citations
Psychoactive mushrooms in the genus Psilocybe have immense cultural value and have been used for centuries in Mesoamerica. Despite the recent surge of interest in these mushrooms due to the psychotherapeutic potential of their natural alkaloid psilocybin, their phylogeny and taxonomy remain substantially incomplete. Moreover, the recent elucidation of the psilocybin biosynthetic gene cluster is...
Frontiers in Psychiatry
January 9, 2024
Terence H. W. Ching, Lucia Amoroso, Calvin Bohner et al.
9 citations
Background To date, few randomized controlled trials of psilocybin with non-directive support exist for obsessive-compulsive disorder (OCD). Results and participant feedback from an interim analysis of an ongoing single-dose trial (NCT03356483) converged on the possibility of administering a higher fixed dose and/or more doses of psilocybin in future trials for presumably greater benefits....
ACS Chemical Neuroscience
January 8, 2024
Alexander M. Sherwood, Elise K. Burkhartzmeyer, Samuel E. Williamson et al.
18 citations
Primary metabolites of mushroom tryptamines, psilocybin and baeocystin (i.e., psilocin and norpsilocin), exhibit potent agonist activity at the serotonin 2A receptor (5-HT2A) in vitro but differ in their 5-HT2A-mediated effects in vivo. In particular, psilocin produces centrally mediated psychedelic effects in vivo, whereas norpsilocin, differing only by the loss of an N-methyl group, is devoid...
Frontiers in Psychiatry
January 8, 2024
N. Jones, Laura M. Wagner, Molly C. Pellitteri Hahn et al.
10 citations
Introduction The use of the psychedelic compound psilocybin in conjunction with psychotherapy has shown promising results in the treatment of psychiatric disorders, though the underlying mechanisms supporting these effects remain unclear. Psilocybin is a Schedule I substance that is dephosphorylated in vivo to form an active metabolite, psilocin. Psilacetin, also known as O-acetylpsilocin or...
bioRxiv (Cold Spring Harbor Laboratory)
January 7, 2024
Ziran Huang, Xiaoyan Wei, Xiaobin Wang et al.
3 citations
preprint
Abstract Recent clinical breakthroughs hold great promise for the application of psilocybin in the treatments of psychological disorders, such as depression, addiction, and obsessive-compulsive disorder. Psilocybin is a psychedelic whose metabolite, psilocin, is a 5-HT 2A receptor agonist. Nevertheless, the underlying mechanisms for the effects of psilocybin on the brain are not fully...
Current Neuropharmacology
January 5, 2024
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic et al.
73 citations
Abstract: Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs))....
bioRxiv (Cold Spring Harbor Laboratory)
January 5, 2024
Ron Shore, K. Dobson, Nina Thomson et al.
3 citations
preprint
Abstract Background and Aims Psilocybin is a psychedelic drug that may hold promise for a wide range of human health conditions, yet the identification of therapeutic processes and mechanisms of action remains exploratory. We conducted a scoping review on pre-clinical behavioural investigations of psilocybin in non-human animals to help determine the behavioural effects of psilocybin in...
Biological Psychiatry
January 5, 2024
Devon Stoliker, Leonardo Novelli, Adeel Razi et al.
42 citations
Our findings suggest that temporary amygdala signal attenuation is associated with mechanistic changes to resting-state network connectivity. These changes are significant for altered cognition and perception and suggest targets for research investigating the efficacy of psychedelic therapy for internalizing psychiatric disorders. More broadly, our study suggests the value of quantifying the...
Research Square
January 4, 2024
Laetitia Vanderijst, Felix Hever, Anne Buot et al.
preprint
Abstract Background: A significant number of individuals with alcohol use disorder remain unresponsive to currently available treatments, which calls for the development of new alternatives. In parallel, psilocybin-assisted therapy for alcohol use disorder has recently yielded promising preliminary results. Building on extant findings, the proposed study is set to evaluate the feasibility and...
Digital Access to Libraries
2024
Nicolas Marquis Fanny Charrasse
Classified by the Convention on Psychotropic Substances, coordinated by the United Nations (UN) in 1971, as dangerous substances with no real therapeutic value, psychedelics have been prohibited since that date in the United States and most European countries. However, over the last two decades there has been a resurgence of interest in them – so much so that some researchers are talking about...
2024
Jo-Hanna Ivers, Katy Tobin, Colm Harrington et al.
OBJECTIVES Understanding variations in knowledge and attitudes of psychiatrists to psilocybin therapy is important for the collective discourse about the potential impact on clinical practice and public health in Ireland. METHODS A 28-item questionnaire was designed based on previous studies and distributed to psychiatrists in Ireland via online mailing lists and at in-person academic events....
2024
Tessa Watford
Depression is a debilitating mental health condition affecting millions worldwide. While antidepressant medications are widely prescribed, they often come with significant side effects and limited efficacy. Tessa Watford, a researcher in the field of neuroscience, has conducted a systematic review exploring the therapeutic potential of psilocybin, a naturally occurring psychedelic compound, for...
Dialogue: A Journal of Mormon Thought
2024
Bridget Verhaaren
“Pretty girls don't buy cocaine,” Greta1 says and laughs as she walks out the front door. My hands and face sting as I stand frozen in the entryway and hear her start the car. I'd asked my twenty-two-year-old daughter where she got the money to feed the addictions she was battling. Over the past three years, she'd chosen a few subpar boyfriends who introduced her to substances, which helped set...
Pharmaceutical journal/The pharmaceutical journal
2024
A “UK first” trial will investigate whether psilocybin — the active ingredient in ‘magic mushrooms’ — can help prevent relapse in people recovering from opioid addiction. The psilocybin study, led by researchers at Imperial College London, will involve 28 participants who have recently undergone detoxification from ‘street’ opioids. Participants will receive psilocybin therapy at the […]
2024
Albert Lehr
Psychedelics are a class of drugs that can occasion similar changes in conscious ex- periences mediated via the G-protein coupled Serotonin 2A receptor. These changes vary from slight distortions in perceptions to pseudohallucinations and the experienced cessation of a personal self distinct from and necessary for conscious experience, known as ego-dissolution. Psychedelics produce positive...
Drug Science, Policy and Law
2024
Torsten Passie
4 citations
The emergence of a so-called psychedelic renaissance has been proposed to characterize the revival of research into (psycho-)therapies using psychedelic drugs. In Europe, the most widespread approach employed in the 1960s and 1970s that involved the use of drugs like LSD and psilocybin as an adjunct to psychotherapy was named according to its main theoretical framework, that is, psychoanalysis...
Annals of Bioethics & Clinical Applications
2024
Correa Rms
1 citation
Psychedelics are a class of hallucinogenic drugs. They have been explored particularly for treatment-resistant psychiatric illnesses. In recent years, advances in psychopharmacology have benefited thousands of patients with some type of mental disorder. Preliminary evidence has shown that psilocybin has shown promise in the treatment of psychiatric disorders, with the support of qualified...
Journal of the Netherlands Society of Toxicology
2024
Marcha Verheijen
1 citation
Depression, affecting over 264 million people globally, presents significant treatment challenges, often due to the limited efficacy and adverse effects of traditional antidepressants and the accessibility issues associated with psychotherapy. Recent advancements in psychedelic-assisted therapy, particularly using psilocybin, a naturally occurring compound found in “magic mushrooms”, shows...